Bristol-Myers Squibb Company (BMY) is listed on NYSE in the Healthcare sector Β· Drug Manufacturers - General industry. The current price is 67.75, up 0.14% from the previous close. Market cap is approximately $138.4B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Bristol-Myers Squibb Company trades at a P/E of 14.92x, within the typical range for mature companies. Whether the multiple sits above or below the sector median is the cleaner relative-value read.
Bristol-Myers Squibb Company's 46.60% ROE places it in the elite band. Companies that sustain ROE above 15% for years usually have a structural moat (brand, network effects, cost advantage).
BMY's D/E at 201.86 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
Bristol-Myers Squibb Company is growing revenue at 5.70% annually. The interesting question is whether pricing power is lifting margins to compensate for the modest top-line.
Bristol-Myers Squibb Company's 3.72% yield is standard. If the company is also buying back stock, evaluate on total shareholder return (dividends + buybacks) rather than yield alone.
Clinical trial outcomes, FDA decisions, and drug-pricing policy drive most of the short-term volatility.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
Bristol-Myers Squibb Company is near its 52-week high (68.64), in the top 3% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
The stock moved within a 2.42% high-to-low band on the day, closing 0.14%. That falls within a typical intraday range.
Bristol-Myers Squibb Company (BMY) is listed on NYSE, with recent volume of 2,193,908 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.